*Staphylococcus aureus* **Bacteremia in Adults** *Staphylococcus aureus* **Bacteremia in Adults**

#### Dima Youssef and Kate Molony Dima Youssef and Kate Molony

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/66225

#### **Abstract**

[27] FDA. *Food Additive Status List*. 2014; Available from: http://www.fda.gov/Food/

[28] Jensen, R.P., et al., *Hidden formaldehyde in e‐cigarette aerosols.* N Engl J Med, 2015. **372**(4):

[29] Hwang, J.H., et al., *Electronic cigarette inhalation alters innate immunity and airway cytokines while increasing the virulence of colonizing bacteria.* J Mol Med (Berl), 2016. **94**(6): pp. 667–79.

[30] Wang, G., *Structures of human host defense cathelicidin LL‐37 and its smallest antimicrobial* 

[31] Neville, F., et al., *Lipid headgroup discrimination by antimicrobial peptide LL‐37: insight into* 

[32] Neville, F., et al., *Electrochemical screening of anti‐microbial peptide LL‐37 interaction with* 

[33] Liu, C., et al., *Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: execu‐*

[34] Sakoulas, G., et al., *Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr)* 

[35] Mishra, N.N., et al., *In vitro cross‐resistance to daptomycin and host defense cationic anti‐ microbial peptides in clinical methicillin‐resistant Staphylococcus aureus isolates.* Antimicrob

[36] Mishra, N.N., et al., *Reduced susceptibility to host‐defense cationic peptides and daptomycin coemerge in methicillin‐resistant Staphylococcus aureus from daptomycin‐naive bacteremic* 

[37] Kullar, R., J.A. McKinnell, and G. Sakoulas, *Avoiding the perfect storm: the biologic and clini‐ cal case for reevaluating the 7‐day expectation for methicillin‐resistant Staphylococcus aureus* 

*bacteremia before switching therapy.* Clin Infect Dis, 2014. **59**(10): pp. 1455–61.

*peptide KR‐12 in lipid micelles.* J Biol Chem,, 2008. **283**(47): pp. 32637–43.

*mechanism of action.* Biophys J,, 2006. **90**(4): pp. 1275–87.

*phospholipids.* Bioelectrochemistry, 2007. **70**(2): p. 205–13.

*tive summary.* Clin Infect Dis, 2011. **52**(3): pp. 285–92.

Agents Chemother, 2011. **55**(9): pp. 4012–8.

*patients.* J Infect Dis, 2012. **206**(8): pp. 1160–7.

*function.* Antimicrob Agents Chemother, 2005. **49**(7): pp. 2687–92.

IngredientsPackagingLabeling/FoodAdditivesIngredients/ucm091048.htm.

pp. 392–4.

116 Frontiers in Frontiers in Staphylococcus Aureus *Staphylococcus aureus*

*Staphylococcus aureus* is an important cause of bacteremia, and *S. aureus* bacteremia con‐ stitutes a serious condition with high morbidity and mortality, secondary to multiple complications including infective endocarditis and embolization. The incidence of bac‐ teremia with *S. aureus* is increasing with more frequent use of medications that lower immune system response, and with the utilization of more invasive medical procedures. In addition, the emergence of resistant *S. aureus* isolates is becoming more common and can negatively affect the outcome of an individual if not diagnosed and managed prop‐ erly. Health care workers encounter *S. aureus* bloodstream infections on a routine basis, and in certain situations, it becomes a very challenging infection to control. Because of the impact this entity has on health care costs and the increased use of resources, it is necessary to highlight the causes, clinical presentation, associated complications, and treatment measures. In this chapter, we will cover each of these points, with somewhat more emphasis on methicillin‐resistant *S. aureus* that is prevalent in both community and hospital settings and is more commonly associated with worsening prognosis and higher mortality.

**Keywords:** *Staphylococcus aureus*, Bacteremia, Sepsis, methicillin susceptible, methicillin resistant, community acquired, hospital acquired
